ALTSTATION.IO

Colgate-Palmolive Company (CL) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$94.75

Change

-0.14%

Market Cap

$76.58B

Avg Volume

6.8M

Company Overview

Colgate-Palmolive Company manufactures and sells a wide array of consumer products, particularly focusing on oral, personal, and home care items. Their offerings include toothpaste, toothbrushes, skincare products, soaps, and household cleaners. Additionally, Colgate-Palmolive has a significant presence in the pet nutrition market with brands like Hill’s Science Diet and Hill’s Prescription Diet. The company’s products target a diverse customer base, including traditional retailers, eCommerce platforms, dental professionals, and pet supply outlets.

Colgate-Palmolive is a market leader in the household and personal care sectors, consistently holding a strong position against competitors like Procter & Gamble and Unilever. Their brand portfolio includes well-known names such as Colgate and Palmolive, which gives them a competitive edge in brand recognition and consumer loyalty. However, they face threats from rising private label products and a growing emphasis on sustainability, forcing the company to adapt in terms of pricing and product formulation.

Currently, Colgate-Palmolive is focused on strategic growth through innovation and sustainability. They are pivoting towards environmentally friendly products and diversifying their portfolios to include more natural ingredients. Recently, the company reported a 5% revenue increase year-over-year, indicating solid demand across its product categories, despite market challenges. Overall, Colgate-Palmolive is positioning itself for long-term growth while navigating competitive pressures in the consumer goods space.

Key Financials

Market Cap

$76.58B

Revenue

$20.38B

EBITDA

$4.92B

Gross Margin

60.1%

Profit Margin

10.5%

Revenue Growth

5.8%

Total Cash

$1.40B

Total Debt

$7.99B

Free Cash Flow

$3.23B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

36.03

Forward P/E

22.86

Beta

0.29

52-Week High

$100.18

52-Week Low

$74.55

EPS

$2.63

50-Day Avg

$81.76

200-Day Avg

$84.37

Price/Book

1414.18

Technical Analysis

Over the past 52 weeks, Colgate-Palmolive Company (CL) has exhibited an overall upward trend, gaining approximately 12.5%, although this growth has not been without fluctuations. Key support is evident around the $85 level, which the stock tested multiple times, while a significant resistance level lies just below $95, where recent peaks have formed. The chart reveals a notable ascending channel pattern from late 2022 into early 2023, indicating a potential bullish sentiment as the stock broke past previous highs. Recently, there has been strong momentum in the last few weeks, culminating in a sharp price increase, suggesting renewed investor interest. Currently, at $94.75, the stock is nearing its 52-week high of approximately $94.41, which indicates that it is trading at a high relative to its 52-week range, potentially setting up for a breakout or a consolidation phase.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Colgate-Palmolive Company (CL) stock in the past week:

1. Strong Q4 2025 Earnings Beat and Optimistic 2026 Outlook Fuel Analyst Upgrades

Colgate-Palmolive (CL) reported better-than-expected fourth-quarter 2025 earnings on January 30, 2026, with adjusted earnings per share of $0.95, surpassing the analyst consensus of $0.91. Quarterly sales reached $5.23 billion, exceeding the Street’s estimate of $5.118 billion. This strong performance, driven by growth in oral care and pet nutrition (excluding private label), led to several analysts maintaining or upgrading their ratings and raising price targets. For instance, B of A Securities and Morgan Stanley maintained “Buy” and “Overweight” ratings respectively, both increasing their price targets to $100.00. Barclays also raised its price target from $83.00 to $88.00 while maintaining an “Equal-Weight” rating, anticipating 2026 growth to exceed that of 2025. Colgate-Palmolive forecasts fiscal 2026 sales between $20.79 billion and $21.61 billion, alongside organic sales growth guidance of 1-4%.

2. Launch of New 2030 Growth Strategy with Focus on Innovation and Digital

During its Q4 2025 earnings call, Colgate-Palmolive unveiled its new “2030 strategy,” transitioning from its previous 2025 plan. This new strategy emphasizes leveraging strong global brands, accelerating science-based innovation, expanding omnichannel demand generation, and doubling down on investments in digital, data, analytics, and AI. The company also highlighted its Strategic Growth and Productivity Program (SGPP) which aims to enable organizational changes and funding for this new strategy.

Market Sentiment and Analyst Recommendations

Bull Case

Colgate just beat Q4 estimates on both earnings and revenue, with adjusted EPS of $0.95 versus $0.91 consensus and sales of $5.23B versus $5.118B expected. The company is guiding 2026 sales between $20.79B and $21.61B with organic growth of 1-4%, and multiple analysts including BofA and Morgan Stanley have raised price targets to $100, suggesting 5.6% upside from current levels. The new 2030 strategy with aggressive product launches planned for 2026, particularly in North America and India, addresses the core problem that 5.8% revenue growth is solid but not exceptional for a company of this size. The stock has already moved 16.8% year-to-date and 18.28% over the last 30 days, showing institutional conviction behind the earnings beat. At a P/E of 36, yes it’s elevated, but the company’s fortress balance sheet with $1.4B in cash and defensive consumer staples positioning make it a reasonable hold for income and stability-focused investors seeking exposure to emerging market growth through brands like Colgate and Hill’s Pet Nutrition.

Bear Case

A P/E of 36 is objectively expensive for a mature consumer staples company growing at 5.8% revenue and guiding 1-4% organic growth in 2026, which suggests deceleration. The debt load of $7.99B against $1.4B in cash leaves limited financial flexibility if consumer spending softens or margin pressures intensify from raw material costs. CEO Noel Wallace sold $4.27M in stock on February 4th, just days after the earnings pop, which is a textbook insider selling signal that the stock may be overheated at current levels near the 52-week high. The guidance range of 1-4% organic growth is wide and leans toward the pessimistic end of the spectrum, signaling management uncertainty about 2026 execution. Innovation pipelines sound good in press releases but Colgate operates in a commoditized market where product differentiation is marginal, and new launches often cannibalize existing products rather than expand the total addressable market.

What to Watch

Monitor the actual execution of the 2026 new product launches, particularly in North America and India, since “aggressive introductions” are only valuable if they drive market share gains and not just volume shuffling. Watch the organic growth rate each quarter against the 1-4% guidance range; if the company trends toward the low end or misses, the valuation multiple will compress quickly given the elevated P/E. Track margin trends closely, as consumer staples companies often sacrifice pricing power to protect volume, and any gross margin compression would be a red flag on the sustainability of current profitability. The debt-to-cash ratio and any refinancing activity should be monitored given the $7.99B debt load; rising interest rates could pressure the balance sheet if debt matures and must be rolled at higher rates. The stock’s technical resistance is at $95-100; a break above $100 with volume would confirm the bullish thesis, but a failure to hold $94.75 and a retest of the $85 support level would suggest the recent rally was a short-squeeze rather than fundamental rerating.

Analyst Consensus

BUY

Based on 19 analyst opinions

Low Target

$84.00

Mean Target

$95.32

High Target

$105.00

Earnings and Financial Data

Sector

Consumer Defensive

Industry

Household & Personal Products

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 24, 2026

EPS (Trailing)

$2.63

Dividend Yield

219.0%

Payout Ratio

78.3%

Frequently Asked Questions

Is CL a good stock to buy?

Analysts recommend a BUY for Colgate-Palmolive (CL) with a target price of $95.32, slightly above the current price of $94.75. The stock’s P/E ratio of 36.03 suggests a premium valuation, but its stability in the consumer defensive sector supports growth.

What is CL’s price target?

The analyst price target for Colgate-Palmolive is $95.32. This target represents a modest upside from the current price of $94.75, indicating potential for slight growth in the near term.

Does CL pay a dividend?

Yes, Colgate-Palmolive offers a substantial dividend yield of 219.0%. This is a strong attraction for dividend-seeking investors, demonstrating the company’s commitment to returning value to shareholders.

What is the 52-week range of CL stock?

Colgate-Palmolive’s stock has traded between $74.55 and $100.18 over the past year. This volatility shows that while the stock can reach higher levels, there are also opportunities for buying near the lower end of this range.

How is CL’s market cap relevant?

Colgate-Palmolive has a market cap of $76.58 billion, indicating it is a large-cap stock within the consumer defensive sector. This size suggests stability, making it a less risky investment compared to smaller companies.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.